Cargando…
Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes
SIMPLE SUMMARY: Canine malignant lymphoma is one of the most common neoplasias in dogs. Even though breed influences the prevalence and prognosis, most cases present resistance to traditional chemotherapy. Canine breeds such as Labrador and Golden Retriever often have a worse prognosis for this reas...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913421/ https://www.ncbi.nlm.nih.gov/pubmed/36766357 http://dx.doi.org/10.3390/ani13030468 |
_version_ | 1784885423272624128 |
---|---|
author | Montaner-Angoiti, Esperanza Marín-García, Pablo Jesús Llobat, Lola |
author_facet | Montaner-Angoiti, Esperanza Marín-García, Pablo Jesús Llobat, Lola |
author_sort | Montaner-Angoiti, Esperanza |
collection | PubMed |
description | SIMPLE SUMMARY: Canine malignant lymphoma is one of the most common neoplasias in dogs. Even though breed influences the prevalence and prognosis, most cases present resistance to traditional chemotherapy. Canine breeds such as Labrador and Golden Retriever often have a worse prognosis for this reason. This high resistance to anticancer drugs makes it necessary to search for other therapies and other therapeutic targets. In this sense, the epigenetic regulators of neoplasia could be a promising object of study in the search for new research advances. ABSTRACT: Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic. |
format | Online Article Text |
id | pubmed-9913421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99134212023-02-11 Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes Montaner-Angoiti, Esperanza Marín-García, Pablo Jesús Llobat, Lola Animals (Basel) Review SIMPLE SUMMARY: Canine malignant lymphoma is one of the most common neoplasias in dogs. Even though breed influences the prevalence and prognosis, most cases present resistance to traditional chemotherapy. Canine breeds such as Labrador and Golden Retriever often have a worse prognosis for this reason. This high resistance to anticancer drugs makes it necessary to search for other therapies and other therapeutic targets. In this sense, the epigenetic regulators of neoplasia could be a promising object of study in the search for new research advances. ABSTRACT: Canine malignant lymphoma is a common neoplasia in dogs, and some studies have used dogs as a research model for molecular mechanisms of lymphomas in humans. In two species, chemotherapy is the treatment of choice, but the resistance to conventional anticancer drugs is frequent. The knowledge of molecular mechanisms of development and progression of neoplasia has expanded in recent years, and the underlying epigenetic mechanisms are increasingly well known. These studies open up new ways of discovering therapeutic biomarkers. Histone deacetylases and demethylase inhibitors could be a future treatment for canine lymphoma, and the use of microRNAs as diagnosis and prognosis biomarkers is getting closer. This review summarises the epigenetic mechanisms underlying canine lymphoma and their possible application as treatment and biomarkers, both prognostic and diagnostic. MDPI 2023-01-29 /pmc/articles/PMC9913421/ /pubmed/36766357 http://dx.doi.org/10.3390/ani13030468 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Montaner-Angoiti, Esperanza Marín-García, Pablo Jesús Llobat, Lola Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes |
title | Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes |
title_full | Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes |
title_fullStr | Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes |
title_full_unstemmed | Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes |
title_short | Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes |
title_sort | epigenetic alterations in canine malignant lymphoma: future and clinical outcomes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913421/ https://www.ncbi.nlm.nih.gov/pubmed/36766357 http://dx.doi.org/10.3390/ani13030468 |
work_keys_str_mv | AT montanerangoitiesperanza epigeneticalterationsincaninemalignantlymphomafutureandclinicaloutcomes AT maringarciapablojesus epigeneticalterationsincaninemalignantlymphomafutureandclinicaloutcomes AT llobatlola epigeneticalterationsincaninemalignantlymphomafutureandclinicaloutcomes |